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Nonrandomized Comparison of Local Urokinase
Thrombolysis Versus Systemic Heparin Anticoagulation for
Superior Sagittal Sinus Thrombosis
M. Wasay, MD; R. Bakshi, MD; S. Kojan, MD; G. Bobustuc, MD; N. Dubey, MD; D.H. Unwin, MD
Background and Purpose—We sought to compare the safety and efficacy of direct urokinase thrombolysis with systemic
heparin anticoagulation for superior sagittal sinus thrombosis (SSST).
Methods—At University at Buffalo (NY) and University of Texas (Dallas, Houston), we reviewed 40 consecutive patients
with SSST, treated with local urokinase (thrombolysis group) or systemic heparin anticoagulation (heparin group). The
thrombolysis group (n520) received local urokinase into the SSS followed by systemic heparin anticoagulation. The
heparin group (n520) received systemic heparin anticoagulation only. Neurological dysfunction was rated as follows:
0, normal; 1, mild (but able to ambulate and communicate); 2, moderate (unable to ambulate, normal mentation); and
3, severe (unable to ambulate, altered mentation).
Results—Age (P50.49), sex (P50.20), baseline venous infarction (P50.73), and predisposing illnesses (P50.52) were
similar between the thrombolysis and heparin groups. Pretreatment neurological function was worse in the thrombolysis
group (normal, n55; mild, n58; moderate, n54; severe, n53) than in the heparin group (normal, n58; mild, n58;
moderate, n53; severe, n51) (P5NS). Discharge neurological function was better in the thrombolysis group (normal,
n516; mild, n53; moderate, n51; severe, n50) than in the heparin group (normal, n59; mild, n56; moderate, n55;
severe, n50) (P50.019, Mann-Whitney U test). Hemorrhagic complications were 10% (n52) in the thrombolysis group
(subdural hematoma, retroperitoneal hemorrhage) and none in the heparin group (P50.49). Three of the heparin group
patients developed complications of the underlying disease (status epilepticus, hydrocephalus, refractory papilledema).
No deaths occurred. Length of hospital stay was similar between the groups (P50.79).
Conclusions—Local thrombolysis with urokinase is fairly well tolerated and may be more effective than systemic heparin
anticoagulation alone in treating SSST. A randomized, prospective study comparing these 2 treatments for SSST is
warranted. (Stroke. 2001;32:2310-2317.)
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Superior sagittal sinus thrombosis (SSST) is an uncommoncause of stroke. The clinical presentation, predisposing
factors, neuroimaging findings, and outcome are extremely
diverse.1,2 Both systemic heparin anticoagulation and local
thrombolysis have been used in the treatment of SSST.2–35
Two controlled trials have shown that heparin is safe and
effective for SSST, even in the presence of intracranial
hemorrhage.3,4 Since 1988, when Scott et al5 reported the first
case of local urokinase thrombolysis in SSST, .70 cases of
local urokinase thrombolysis have been reported.7–31,34,35
These studies are nonrandomized and uncontrolled but sug-
gest that urokinase thrombolysis is safe and effective and is
usually associated with favorable outcome even in hemor-
rhagic venous infarction. Systemic heparin anticoagulation is
considered the standard therapy for SSST6 because no data
See Editorial Comment, page 2317
are available regarding the safety and efficacy of
thrombolysis in comparison to systemic heparin anticoagula-
tion. We reviewed our experience in treating SSST to
compare the safety and efficacy of direct urokinase
thrombolysis versus systemic heparin anticoagulation alone.
Subjects and Methods
Seventy consecutive patients with dural venous sinus thrombosis
were retrospectively identified at 3 institutions (University at Buf-
falo–State University of New York; University of Texas Southwest-
ern Medical Center, Dallas; University of Texas, Houston) during
1981–1997. Forty of these patients were included in the study
because they had SSST and were treated with either local urokinase
(thrombolysis group; n520) or systemic heparin anticoagulation
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alone (heparin group; n520) (Tables 1 and 2). One of these patients
(thrombolysis group, patient 1; Table 2) was described in detail in a
previous publication.36 The remaining 30 patients were excluded
because they did not receive either heparin or urokinase. All patients
in the thrombolysis group were from Dallas (n518) and Houston
(n52). The decision to treat patients with urokinase was based on
physician preference and availability of thrombolytic treatment. All
patients included from Buffalo were in the heparin group because the
endovascular physicians had not established an approved protocol or
previous experience with thrombolytic treatment for SSST. The
diagnosis of SSST was confirmed by cerebral angiogram in all
patients in the thrombolysis group and in 11 patients in the heparin
group (Table 2). The diagnosis was based on MRI/MR venography
(MRV) in all remaining patients in the heparin group (Table 2).
There was a discrepancy between results of MRI and angiography in
patients for whom both tests were performed. Angiography was
more sensitive in the diagnosis of transverse sinus thrombosis (TST)
and SSST than MRI/MRV (Table 2). With the use of the best
available data from the diagnostic modalities that were used in each
patient, the heparin group showed SSST alone in 7 patients,
SSST1TST in 9 patients, and SSST1deep cerebral venous throm-
bosis (DCVT) or SSST1cortical venous thrombosis (COVT) in 4
patients. By comparison, the thrombolysis group had SSST alone in
3 patients, SSST1TST in 14 patients, or SSST1DVCT/COVT in 3
patients. Eleven angiograms performed in the heparin group showed
SSST alone in 3 patients, SSST1TST in 4 patients, and
SSST1DCVT/COVT in 4 patients. Cerebral angiograms in the
thrombolysis group showed SSST alone in 3 patients, SSST1TST in
14 patients, and SSST1DCVT/COVT in 3 patients. While the
thrombosis appears more extensive in the thrombolysis group (more
patients had involvement of $2 sinuses than in the heparin group),
this must be interpreted with caution because more patients had
angiography in the thrombolysis group.
All patients in the thrombolysis group received local thrombolysis
into the superior sagittal sinus (SSS). A 5F angiographic catheter and
guidewire were placed in the internal jugular vein via femoral vein
catheterization. A Tracker-18 microcatheter (Target Therapeutics)
was advanced over the guidewire into the SSS. The catheter was
advanced into thrombus as much as possible. Through this catheter,
a urokinase bolus (250 000 U) was infused into the SSS, followed by
continuous urokinase infusion (80,000 U/h). Only 1 patient (patient
18, aged 4 years) received a 50 000 U bolus followed by 10 000 U/h
infusion (the dose was lowered for body weight). All other patients
received the higher dose. The patients were then transferred to an
intensive care unit with the catheter secured into the SSS with
continuous infusion into SSS. A repeated angiogram was performed
daily in each patient. The end point for urokinase infusion (patency
of the SSS) was successfully achieved in all 20 patients. Thrombol-
ysis of deep venous system and transverse sinus was achieved in
some patients before the patency of the SSS was achieved, but the
end point of infusion was patency of SSS. The infusion was
discontinued after patency of SSS was identified on the repeated
angiogram. In 3 patients (patients 3, 13, 18) patency of SSS was
identified on first follow-up angiogram. The catheter was further
advanced into the thrombus if possible after repeated angiograms.
The duration of infusion was 16 to 84 hours (mean, 52 hours), as
detailed for each patient in Table 2. This duration does not neces-
sarily reflect time to achieve patency of SSS, but it represents the
time between first angiogram (start of treatment) and last angiogram
(when patency of SSS was first identified). While none of the
patients received concomitant heparinization, the thrombolysis was
always followed by intravenous heparin therapy, which was started
within 24 hours of thrombolysis. The doses of heparin were adjusted
to maintain a partial thromboplastin time (PTT) between 50 and 60
seconds. The heparin group received only systemic heparin to
maintain a PTT between 50 and 60 seconds (Table 2). This level of
anticoagulation was well maintained in the majority of patients with
repeated adjustments in heparin doses. All patients in the
thrombolysis group and 16 patients in the heparin group were
subsequently started on long-term oral anticoagulation (warfarin
therapy). The exact details about the duration of long-term oral
anticoagulation were not available.
Clinical presentation, predisposing factors, neuroimaging find-
ings, and outcome were determined by chart review (Tables 1 and 2).
TABLE 1. Heparin- vs Urokinase-Treated Patients With SSST
Heparin
(n520)
Urokinase
(n520) P
Age, mean (range) 37 y (1 d–65 y) 34 y (4–61 y) 0.49
Sex 3 Male (15%) 8 Male (40%) 0.20
Venous infarction pretreatment on CT/MRI 7 (35%) 7 (35%)
Nonhemorrhagic 3 4 0.73
Hemorrhagic 4 3 0.73
Hypercoaguable/comorbid state 9 12 0.52
Admission (pretreatment) neurological deficit 0.20
Normal 8 5
Mild 8 8
Moderate 3 4
Severe 1 3
Discharge (postreatment) neurological deficit 0.019
Normal 9 16
Mild 6 3
Moderate 5 1
Severe 0 0
Hemorrhagic complications 0 2 (10%) 0.49
Hospital stay, mean (range), d 13.5 (2–33) 12 (6–30) 0.79
Death None None
Recurrence 3 (15%) 1 (5%) 0.61
Values are number of patients unless indicated otherwise.
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TABLE 2. Clinical and Imaging Data in Heparin and Thrombolysis Groups
Case
No.
Age,
y/Sex
Rx/PTT or
Duration, h*
Admission Discharge
CT MRI/MRV Angiography Etiology
Hospital
Stay, d
Long-Term
Follow-Up
Symptoms Exam
Neuro-
score Exam
Neuro-
score
Time,
mo
Symptoms/
Exam
Heparin group
1 27/F H; 40–70 HA, DVT WNL 0 WNL 0 N/P SSST N/P Protein C 17 10 WNL
2 26/F H; N/A HA, SZ HS 1 WNL 0 Parietal HVI Multiple HVI, SSST N/P Bechet’s 20 N/A N/A
3 39/F H; 38–100 HA, SZ, HP HP, ENC 2 HP 2 Frontal HVI Frontal HVI SSST Protein S 26 6 HP
4 33/F H; 44–67 HA WNL 0 WNL 0 N/P SSST, TST SSST Idiopathic 7 N/A N/A
5 38/F H; 40–76 HA, HS IICP 0 WNL 0 N/P SSST N/P Idiopathic 10 4 WNL
6 30/F H; 48–68 HA WNL 0 WNL 0 WNL TST SSST, TST Autoimmune
hemolytic
anemia
7 8 WNL
7 55/M H; N/A HA, HP HP 2 HP 2 SSST, TST SSST, TST N/P Idiopathic 12 10 Mild HP
8 42/F H; 56–66 HA, HP HP 1 HP 1 SSST, DCVT SSST, TST SSST Idiopathic 10 1.5 HP
9 4 mo/M H; N/A Fever, ENC HP 1 HP 2 Parietal NHVI SSST, TST, DCVT N/P Idiopathic 29 6 HP
10 55/F H; 44–60 HA, SZ WNL 0 AP, HP 2 Temporal
NHVI
SSST, temporal NHVI N/P Malignancy 13 7 HP
11 34/F H; 33–100 HA, BV AT 1 AT 2 N/P SSST, TST SSST, COVT Lupus 15 3 Mild AT
12 1 d/M H; N/A SZ, HT HP 3 HT 1 N/P SSST N/P Protein C 33 12 WNL
13 42/F H; 50–70 SZ, DY DY, PP 2 HP 1 Bifrontal HVI SSST, bifrontal HVI N/P Idiopathic 20 4 Mild HP
14 25/F H; 45–60 HA WNL 0 WNL 0 WNL SSST, TST N/P Idiopathic 5 2 WNL
15 23/F H; 50–66 HA WNL 0 WNL 0 Temporal HVI SSST, TST, temporal
HVI
SSST, TST Idiopathic 4 3 Mild AT
16 57/F H; 62 HA WNL 0 WNL 0 N/A SSST SSST, TST, DCVT Idiopathic 6 3 WNL
17 39/F H; 40–66 HA, HP HP 1 HP 1 N/A SSST SSST, DCVT Idiopathic 8 3 HP
18 65/F H; 70 HA, DP ENC, IICP 1 IICP 1 N/P SSST SSST, TST Lupus 2 N/A N/A
19 24/F H; 36–54 HA, SZ ENC 1 WNL 0 N/A Bifrontal NHVI, SSST SSST, TST, DCVT Postpartum 5 7 WNL
20 53/F H; 44–80 HA, SZ, ENC ENC 1 HP 1 SSST N/P SSST, TST Idiopathic 8 6 SZ
Thrombolysis group
1 30/F U; 70 HA, HP HP IICP 1 WNL 0 SSST, DCVT N/P SSST, TST DI-lithium36 9 3 WNL
2 53/F U; 64 SZ, ENC, HP HH, HP 2 HP 1 Parietal HVI Biparietal HVI, SSST SSST, TST HC 30 2 HP
3 23/M U; 18 HA IICP, HS 1 WNL 0 WNL White matter
NHVI, SSST
SSST, TST Lupus 6 7 WNL
4 38/M U; 44 HA, DP IICP, AT 2 WNL 0 N/P SSST SSST, TST HC 8 3 SZ
5 36/M U; 52 HA, DP IICP 1 WNL 0 N/P SSST SSST, TST PNH 12 10 WNL
6 32/F U; 40 HA WNL 0 WNL 0 WNL SSST, TST SSST, TST Lupus 7 12 WNL
7 48/M U; 66 HA, HS HS 1 WNL 0 N/P SSST, TST SSST, TST HC 8 1 WNL
8 28/F U; 65 HA IICP 1 WNL 0 WNL SSST SSST, TST Idiopathic 7 N/A N/A
9 23/F U; 70 SZ, AP, HP AP, HP 3 HP 1 TH-HVI TH-HVI, SSST SSST, DCVT UC 11 6 Mild HP
10 27/F U; 58 HA WNL 0 WNL 0 DCVT SSST SSST, TST Idiopathic 9 12 WNL
11 34/F U; 50 HA, DP ENC, IICP 2 WNL 0 DCVT SSST, TST SSST, TST UC 7 3 WNL
12 35/M U; 39 HA, SZ WNL 0 WNL 0 N/A Frontal NHVI SSST, TST Idiopathic 8 N/A N/A
13 38/M U; 19 HA, SZ, HP HP 2 HP 1 BG-NHVI BG-NHVI, SSST SSST Idiopathic 22 6 Mild HP
14 23/F U; 70 HA, SZ IICP 1 WNL 0 N/P Parietal NHVI, SSST SSST, TST Idiopathic 17 1 WNL
15 61/F U; 84 HA, BV HP 1 WNL 0 TST SSST, TST SSST, TST Idiopathic 10 10 WNL
16 32/F U; 68 HA, dizzy WNL 0 WNL 0 N/P SSST SSST Postpartum 7 3 WNL
17 55/F U; 38 HA, HP AP, HP 3 WNL 0 WNL SSST SSST Idiopathic 15 4 WNL
18 4/M U; 16 HA, ENC WNL 0 WNL 0 SSST SSST, DCVT SSST, DCVT Nephrotic
syndrome
10 N/A N/A
19 29/M U; 72 HA, SZ, HP HP, ENC 3 HP 2 HVI N/P SSST, COVT UC 29 15 HP
20 38/F U; 48 HA, SZ HP 1 WNL 0 WNL SSST SSST, TST Idiopathic 12 1.5 WNL
AP indicates aphasia; AT, ataxia of gait; BG, basal ganglia; BV, blurred vision; COVT, cortical venous thrombosis; DCVT, deep cerebral venous thrombosis; DH,
dehydration; DI, diabetes insipidus; DP, diplopia; DVT, deep venous thrombosis of leg; DY, dysarthria; ENC, encephalopathy; H, heparin therapy alone; PTT range;
HA, headache; HC, homocysteinuria; HH, homonymous hemianopsia; HP, hemiparesis; HS, hemisensory loss; HT, hypotonia; HVI, hemorrhagic venous infarct; IICP,
increased intracranial pressure (eg, papilledema, sixth nerve paresis); N/A, not available; neuroscore, ordinal rating of neurological deficit (see Subjects and Methods);
NHVI, nonhemorrhagic venous infarct; N/P, not performed; PP, paraparesis; Protein C, protein C deficiency; SZ, seizures; TH, thalamic; U, urokinase therapy; duration
of infusion (h); UC, ulcerative colitis; and WNL, within normal limits.
*PTT for heparin group; duration of infusion for thrombolysis group.
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The neurological dysfunction was rated at admission and discharge
on a 4-point ordinal scale of neuroscores: 0, normal; 1, mild (able to
ambulate and communicate); 2, moderate (unable to ambulate,
normal mentation); and 3, severe (unable to ambulate, altered
mentation) (Tables 1 and 2). Determination of neuroscores in the 3
pediatric patients (heparin group, n52; thrombolysis group, n51)
was more subjective and was based on the level of consciousness and
the presence of focal neurological deficits. Two reviewers separately
scored the neurological deficits. The reviewers were blinded in
regard to the patient’s treatment. Ninety percent agreement of
neuroscores was found between the 2 reviewers. In 10% of cases, a
third reviewer resolved disagreements in neuroscores. Secondary
outcome measures included mortality, length of hospital stay, com-
plications, and recurrence of SSST (Tables 1 and 2). For recurrence,
MRI/MRV evidence of recurrent or more extensive thrombosis was
necessary to make a diagnosis. Many of the patients were lost to
follow-up and, unfortunately, long-term follow-up was not available.
The Mann-Whitney U test for nonparametric data or the Fisher’s
exact probability test for categorical data assessed group differences.
P,0.05 was considered statistically significant.
Results
Baseline characteristics and outcome of the patients are
shown in Tables 1 and 2. The 2 groups were well matched in
terms of age, sex, the presence of venous infarction on
pretreatment CT/MRI scans, underlying risk factors for
SSST, and pretreatment comorbidity. The duration of symp-
toms ranged from 1 day to 6 months in the thrombolysis
group and 1 day to 4 months in the heparin group. All patients
with chronic symptoms had recent worsening or new neuro-
logical symptoms before presentation. Hemorrhagic venous
infarcts were identified in 4 heparin group patients and in 3
thrombolysis group patients. Nonhemorrhagic venous infarcts
were identified in 3 patients in the heparin group and 4
patients in the thrombolysis group. Hypercoagulable states
were present in 12 (60%) of the thrombolysis group and in 9
(45%) of the heparin group. A comparison of all raw
neuroscores on the 4-point scale showed that admission
neurological function (neuroscore) was slightly worse in the
thrombolysis group but not statistically significantly different
than that of the heparin group (Table 1). A comparison of all
raw neuroscores on the 4-point scale showed that discharge
neurological function was better in the thrombolysis group
than in the heparin group (P50.019, Mann-Whitney U test).
A post hoc analysis was also performed to further define the
results. We categorized the discharge neuroscores into 2
categories, normal or mild versus moderate or severe, giving
a nonsignificant Fisher’s exact probability test (P50.18)
result between the 2 treatment groups.
Importantly, no worsening of hemorrhage or neurological
deficit was seen in 3 patients with preexisting hemorrhagic
infarcts in the thrombolysis group. Three patients in the
heparin group had worsening of neurological function despite
therapeutic anticoagulation (patients 9, 10, 11). One patient in
the heparin group (patient 9) with hemorrhagic infarction
showed worsening of the neurological deficit without any
increase in size of the infarction or bleeding. Another patient
in the heparin group (patient 10) presented with headache and
seizures and then subsequently developed aphasia and hemi-
paresis. Initial CT scan showed a nonhemorrhagic infarct, but
MRI showed SSST and a large temporal lobe infarct. It is
likely that the neurological deterioration was related to
extension of venous infarction or unwitnessed seizures and
not due to the systemic malignancy. The patient was not
considered a candidate for thrombolysis because of underly-
ing malignancy.
Fifteen percent (n53) in the heparin group developed
complications of the underlying disease (hydrocephalus re-
quiring ventricular shunt, refractory papilledema requiring
optic nerve fenestration, prolonged status epilepticus requir-
ing pentobarbital coma). There were no complications of the
underlying disease in the thrombolysis group. No deaths
occurred in either group. Recurrence rate of SSST was 5%
(n51) in the thrombolysis group and 15% (n53) in the
heparin group (P50.61, Fisher’s exact probability test).
Recurrence was defined as clinical (new symptoms or recur-
rence of previous symptoms) and neuroimaging (MRI/MRV)
evidence of recurrent or more extensive SSST. All 4 patients
with recurrence presented within 3 months of discharge, and
the diagnosis of SSST was established by MRI/MRV. One
patient (thrombolysis group) had extensive SSST and under-
went a repeated urokinase thrombolysis with recanalization
of SSS. In all patients, recurrence was associated with
subtherapeutic anticoagulation secondary to noncompliance
with warfarin therapy. There was no significant difference
between the 2 groups in recurrence rate and length of hospital
stay (Table 1).
Two patients in the thrombolysis group developed hemor-
rhagic complications. One patient developed a subdural
hematoma, which was successfully treated conservatively.
The other patient, with paroxysmal nocturnal hemoglobinuria
(PNH), developed retroperitoneal hemorrhage and was
treated successfully with blood transfusions. We believe that
retroperitoneal hemorrhage in the patient with PNH and
SSST was due to a combination of coagulopathy associated
with PNH and the use of thrombolytic therapy. Thus, the
hemorrhagic complications were 10% (n52) in the
thrombolysis group and none in the heparin group (P50.49,
Fisher’s exact probability test) (Table 1).
Discussion
This is the first study comparing the relative safety and
efficacy of thrombolysis versus systemic heparin anticoagu-
lation for SSST. In this review local urokinase was relatively
well tolerated in all 20 patients. Recanalization was docu-
mented in all patients receiving urokinase. Multiple case
reports and series have shown the safety and efficacy of
urokinase thrombolysis in SSST.7–31,34,35 A review of this
literature, including the current cases, is provided in Table 3.
Heparin has long been part of the standard therapy for
SSST2,6 and has been the subject of several large se-
ries,2,4,5,32,33 as summarized in Table 4. The question of the
safety and efficacy of thrombolytic therapy in comparison to
heparin anticoagulation has been raised recently.6 This study
is an effort to address this important question.
Intracranial hemorrhage is a feared and limiting complica-
tion of thrombolytic therapy. Three patients in our
thrombolysis group had pretreatment hemorrhagic infarcts.
No worsening of these hemorrhages or progressive neurolog-
ical deficits were identified in these patients. Two patients in
our thrombolysis group developed hemorrhagic complica-
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tions (unrelated to the venous thrombosis). We reviewed 96
cases of SSST (including our series) treated with local
thrombolysis (urokinase, n572; tissue plasminogen activator,
n523; streptokinase, n51), as summarized in Table 3.
Eighty-eight of these patients (92%) had a good recovery, 1
patient died, and 5 patients had worsening of intracranial
hemorrhage without a fatal outcome (Table 3). Seven patients
developed new hemorrhages (retroperitoneal bleed, n53;
intracerebral hemorrhage, n52; subdural hemorrhage, n51;
hematuria, n51) (Table 3). Horowitz et al7 described 13
TABLE 3. Studies of Thrombolysis for SSST
Study n Agent
Hemorrhage Outcome
Major ComplicationsPretreat Worsen* N/A Good Poor Death
Horowitz7 13 Urokinase 4 0 1 11 1 Retroperitoneal bleed (n51)
Frey8 12 tPA 7 2 9 3 None
Kim9 9 tPA 1 0 9 Retroperitoneal bleed (n51)
Smith10 7 Urokinase N/A 7 None
Tsai11 5 Urokinase 0 4 1 None
Kasner12 3 Urokinase 3 0 3 None
Barnwell13 3 Urokinase N/A 3 None
Smith14 2 Urokinase 1 0 2 None
Rael15 1 Urokinase 1 0 1 None
Kermode16 1 Streptokinase 0 1 None
Renowdn17 1 tPA 0 1 None
Spearman18 2 Urokinase 1 1 2 None
Crawford19 1 Urokinase N/A 1 N/A
Khoo20 1 Urokinase 0 1 None
Gerszten21 1 Urokinase 1 1 1 Brain hemorrhage (n51)
Griesemer22 1 Urokinase 0 1 None
Eskridge23 1 Urokinase 0 1 Brain hemorrhage (n51)
Manthous24 1 Urokinase 0 1 None
Takami25 1 Urokinase 0 1 None
D’Alise26 1 Urokinase 0 1 None
Niwa27 1 tPA 0 1 None
Kuether28 1 Urokinase 1 0 1 None
Smadja29 1 Urokinase 0 1 Hematuria (n51)
Satake30 1 Urokinase 0 N/A 1 N/A
Manzione31 1 Urokinase 0 0 1 None
Chow34 2 Rheolysis1urokinase 2 1 2
Gurley35 2 Urokinase 0 0 2
Wasay
(current
report)
20 Urokinase 3 0 19 1 0 Retroperitoneal bleed (n51)
Subdural hemorrhage (n51)
Total 96 25 5 1 88 6 1 7
N/A indicates not available.
*Exacerbation of hemorrhagic component.
TABLE 4. Large Studies of Heparin Treatment for SSST
Author n Agent
Hemorrhage Outcome
Major ComplicationsPretreat Worsen* Good Poor Death
Einhaupl4 77 Heparin 27 N/A N/A N/A 4 Intracranial bleed (n58)
Brucker32 42 Heparin 22 0 39 2 1 N/A
de Bruijn3 30 LMWH 15 N/A 24 4 2 Gastric bleed (n51)
Ameri2 82 Heparin N/A N/A N/A N/A 0 N/A
DeVeber33 22 Heparin/LMWH 6 N/A N/A N/A 0 N/A
N/A indicates not available.
*Exacerbation of hemorrhagic component.
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patients, 4 of whom had pretreatment brain hemorrhages
(Table 3). No worsening was seen after thrombolysis. Kim
and Suh9 described 9 patients, 1 of whom had pretreatment
hemorrhage that remained stable (Table 3). Kasner and
colleagues12 described 3 patients with hemorrhages with no
worsening after thrombolysis (Table 3). Frey et al8 recently
described 12 patients treated with recombinant tissue plas-
minogen activator (tPA), 7 of whom had pretreatment hem-
orrhages (Table 3). Two of these patients showed nonfatal
worsening of hemorrhage after thrombolysis. A slightly
increased risk of hemorrhage in the patients of Frey et al
could be attributed to a more rapid and more potent effect of
tPA and the concomitant use of heparinization during
thrombolysis. Chow et al34 described 2 patients treated with
rheolytic thrombectomy and direct urokinase thrombolysis.
Both patients had pretreatment intracranial hemorrhages. One
patient showed worsening of preexisting hemorrhage and
development of a new hemorrhagic infarction. Both of these
patients had excellent recovery (Table 3).
We believe that there is increased risk of hemorrhage in
patients treated with urokinase, as shown in our series. Large
studies on the use of heparin in SSST are summarized in
Table 4. Einhaupl et al4 reported a series of 102 patients, 77
of which were treated with heparin (dose-adjusted heparin,
n556; low-dose or intermittent heparin, n521). Eight pa-
tients developed intracranial hemorrhage after the onset of
anticoagulation therapy. In our series, 3 patients in the
heparin group had worsening of their neurological deficit
despite therapeutic anticoagulation. One of these patients had
pretreatment intraparenchymal hemorrhage, which did not
show any change by serial CT. Neurological worsening is
common in patients with SSST and is usually attributed to
clot progression, involvement of deep cerebral veins, hema-
toma formation, or the development of venous infarcts.1,2 It
has been proposed that patients with neurological worsening
are the most appropriate candidates for local thrombolytic
therapy.6 The clinical outcome in our heparin group is
comparable to previously reported series (Table 4). In our
series, 55% of the heparin group had a neurological deficit at
discharge. Two randomized trials reported the use of heparin
or low-molecular-weight heparin (LMWH) in SSST. Among
30 patients treated with LMWH, 2 died, 24 had a good
recovery, and 4 had a poor outcome (Table 4).3 Three other
nonrandomized series described 146 patients treated with
heparin and LMWH (Table 4).2,32,33 The data on neurological
outcome are not well reported in these studies.
It has been suggested that extent of clot or thrombosis may
be related to outcome. We did not perform a statistical
analysis of the extent of clot in the 2 groups because of the
limited sample size. Evaluation of the extent of thrombosis by
cerebral angiogram was performed in only 11 patients in the
heparin group compared with 20 patients in the thrombolysis
group. Many patients in both groups had involvement of $2
sinuses or deep cerebral veins and thus seem comparable. The
duration of symptoms in the thrombolysis group ranged from
1 day to 6 months, but all patients with chronic symptoms had
recent worsening or developed new neurological symptoms
or deficits. We believe that despite chronicity of symptoms in
these patients, there was a component of new or worsening
thrombosis that was probably responsible for their acute
presentation. The fact that patency of the SSS was achieved in
all patients after thrombolysis supports our hypothesis.
Complications in the thrombolysis group were directly
related to treatment and are comparable to previous reports.
The patient with retroperitoneal hemorrhage and PNH was
treated with transfusions and corticosteroids (for PNH) and
was started on warfarin before discharge. The other patient
with a subdural hematoma was managed conservatively and
ultimately received warfarin as an outpatient. Complications
in the heparin group were manifestations of the underlying
disease and were not directly related to heparin therapy. One
patient in the heparin group had refractory papilledema
requiring optic nerve fenestration. It is possible that
thrombolytic therapy with recanalization of the SSS could
have prevented these complications. Papilledema was present
in 5 (25%) of the patients in the thrombolysis group, but none
required optic nerve fenestration.
In contrast to previously reported series, 5 patients (25%)
in our study underwent urokinase thrombolysis despite a
normal neurological examination, although these patients had
significant symptoms of SSST. It has been suggested that
local thrombolysis should be used only for patients with
moderate disability or a worsening neurological deficit de-
spite effective systemic anticoagulation.6 Another view is that
the course of SSST is unpredictable and often relentless, and
therefore thrombolytic therapy should be instituted as soon as
the diagnosis is confirmed, even in patients with mild
neurological deficits.7 We believe that disability in this
condition is often related to venous infarction and hemor-
rhage, as illustrated in our series. We believe that local
urokinase thrombolysis should be instituted promptly, if
available. Otherwise, patients with SSST should be treated
with heparin anticoagulation. The decision to administer
thrombolysis to these patients was based on our clinical
experience that the clinical course of SSST is often unpre-
dictable and early, aggressive treatment to recanalize the SSS
is relatively well tolerated and promotes recovery. A prospec-
tive, randomized trial is warranted to compare safety and
efficacy of these 2 treatments.
The matching of baseline characteristics between our 2
groups makes it unlikely that the differences were due to a
selection bias. If anything, the thrombolysis group was
disadvantaged by slightly worse pretreatment neurological
deficit and possibly more extensive thrombosis. The diagno-
sis of SSST was confirmed by angiography or MRI/MRV in
all patients. This study is limited by the retrospective ap-
proach with nonrandomized treatment groups and a relatively
small number of patients. Neurological deficit was deter-
mined by chart review, and this may have introduced vari-
ability in outcome assessment. To overcome this limitation,
we did not use a detailed standardized disability scale for
evaluation of neurological deficit. Instead, we used a simple
scale to grossly measure neurological deficit using informa-
tion readily documented in charts. Baseline characteristics
were matched in the 2 groups, but as a result of the
multicenter and retrospective nature of the study, patients did
not have similar evaluations for etiology. Because of the
heterogeneous patient population and small sample size, the
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chance of finding a statistically significant difference in
baseline characteristics is small. An important problem with
local thrombolysis therapy is limited availability. In compar-
ison, heparin and LMWH are widely available and do not
require a specially trained physician or angiography suite for
institution of therapy. These factors are important in clinical
decision making. Another limitation of our study is the
unavailability of long-term follow-up. Our statistical analysis
was done at discharge, which showed improved outcome in
urokinase-treated patients. We do not know whether the
heparin group achieved the same long-term neurological
function as the thrombolysis group months or years later.
Therefore, we cannot evaluate whether local thrombolysis
only increases the rate of recovery rather than the magnitude
of recovery. Properly designed, larger, randomized prospec-
tive studies with long-term follow-up will be necessary to
confirm and extend our findings. The role of urokinase as a
thrombolytic agent is uncertain because the drug was recently
removed from the US and Canadian markets. The company is
evaluating the possibility of bringing the drug back to the
market. The use of tPA has been reported in recent literature
with results comparable to those with urokinase in
SSST.8,9,17,27 However, there is less information on the use of
tPA in SSST, and further experience is desirable for a
complete evaluation of this therapy.
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Editorial Comment
Cerebral Venous Thrombosis and Thrombolysis
Cerebral venous thrombosis is an uncommon disorder. It can
manifest as isolated raised intracranial pressure presenting with
headache and papilledema associated with a relatively benign
course. Alternatively, it can present as a fulminating and rarely fatal
stroke syndrome, with severe headache, seizures, and focal neuro-
logical signs developing within hours to days.
Heparin, first suggested by Stansfield,1 has been the mainstay of
treatment. Patients improve within hours of commencing treatment
and well before recanalization of thrombosed sinuses occurs. Re-
covery can be excellent even in the absence of recanalization. Two
randomized trials of anticoagulation have given conflicting results.
The first2 demonstrated a benefit of intravenous heparin, the second3
failed to show a benefit with low molecular weight heparin.
However, in the latter study, the 2 groups were not evenly matched:
there were more patients with isolated raised intracranial pressure in
the placebo group. Despite this, most authorities would recommend
treatment with intravenous heparin followed by a 3- to 6-month
course of anticoagulation with warfarin.4. These studies also
showed that some patients do well even without treatment.
Thrombolysis was first suggested by Scott et al,5 and since then
a number of reports have established the relative safety of
thrombolysis even in the presence of hemorrhagic infarction or
frank parenchymal hematoma. These studies have also demon-
strated that thrombolysis can rapidly restore the patency of the
thrombosed venous sinuses.2,3
In their article, Wasay and colleagues report the results of a
comparison of thrombolysis versus anticoagulation. The study
compared patients treated with intravenous heparin alone to those
treated with intravenous thrombolysis (use of urokinase directly into
the occluded venous sinus followed by intravenous heparin). Their
study confirms previous observations that thrombolysis is very
effective in recanalizing occluded venous sinuses and relatively
safe. The authors argue that the thrombolytic group had more
extensive thrombosis and were more severely affected before
treatment and had a greater rate of recanalization and a better
outcome after treatment compared with the heparin group. How-
ever, the study was nonrandomized and retrospectively assigned a
severity of neurological deficit using a nonstandardized scale.
Although the extent of venous thrombosis was greater in the
thrombolytic group, this may relate to the greater use of formal
angiography in the thrombolytic group. Formal angiography is, as
the authors admit, more sensitive than MRI in detection of trans-
verse and superior sagittal sinus thrombosis. Although there was a
greater rate of recanalization, this has yet to be shown to relate to
clinical outcome. An increased risk of hemorrhage with
thrombolytic therapy is recognized6 and was also seen in this study,
in which there was a 10% incidence of hemorrhagic complications
with thrombolytic therapy, whereas with heparin therapy there were
no hemorrhagic complications.
Although the recurrence rate was higher in the group treated with
heparin, the authors admit that this was related to inadequate
anticoagulation. This study, however, fails to convincingly demon-
strate that thrombolysis improves outcome compared with heparin.
Thrombolysis is more expensive and would be available only in
major centers, whereas heparin is cheaper and can be administered
in any hospital. Patients treated with heparin usually make an
excellent recovery, with improvement occurring before recanaliza-
tion occurs. A good outcome can occur in the absence of complete
recanalization.
On the other hand, as the authors conclude, it is now time for
those who propose thrombolysis to conduct a multicenter, random-
ized, controlled trial to prove that thrombolysis with either urokinase
or recombinant tissue plasminogen activator directly into the oc-
cluded venous sinus is more effective than treatment with intrave-
nous heparin. The patients should be stratified into 2 groups: those
with isolated intracranial hypertension and those presenting with
stroke syndrome. Strict criteria need to be established, with full
anticoagulation using heparin followed by 6 months of warfarin
versus a standardized bolus dose of a thrombolytic agent with
clearly defined bolus doses, rates of administration, and duration of
thrombolysis. The definition of efficacy should not be recanaliza-
tion; rather, it should be a standardized stroke outcome scale and, in
addition, neuropsychological assessment of cognitive function. Un-
til such a study is undertaken, these authors will continue to use
intravenous heparin as the treatment of first choice. In our experi-
ence, a poor outcome relates more to a delay in diagnosis.
Peter Gates, MBBS, FRACP, Guest Editor
Geelong and St Vincent’s Hospitals
Richard Gerraty, MD, FRACP, Guest Editor
St Vincent’s Hospital
Victoria, Australia
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